Dupixent Lawsuits for T-Cell Lymphoma [2026 Update]

Our Firm Is Actively Reviewing Dupixent Claims

See If You Qualify!

People are filing Dupixent lawsuits alleging that the drug (dupilumab) can increase the risk of developing cutaneous T-cell lymphoma (CTCL), yet they were not warned of this possible risk. Dupixent is a prescription biologic used to treat a range of chronic inflammatory conditions, including atopic dermatitis, eczema, COPD, asthma, and other skin and lung conditions.

People who received Dupixent injections and later developed CTCL allege there is a connection between the drug and developing this rare type of blood cancer. Researchers have been studying whether Dupixent can increase the risk of or unmask certain types of lymphoma. Plaintiffs in Dupixent lawsuits allege that the drug’s manufacturers, Sanofi, Genzyme, and Regeneron, should have known about this possible risk. They say that the companies should have warned patients and physicians.

On this page, you will learn what the Dupixent lawsuit is about, research about Dupixent and cutaneous T-cell lymphoma, and the legal grounds of lawsuits. You will also find studies examining the possible relationship between Dupixent and lymphoma. This article also provides information on who can file a Dupixent lawsuit, filing deadlines, and possible compensation and settlements.

On This Page

Dupixent (Dupilumab) Lawsuit, Regulatory, & Research 2026 Updates

July 1, 2026: 26 Lawsuits Consolidated in Dupixent MDL, Judge Schedules Important Case Deadlines

As of July 1, 2026, there are 26 lawsuits that have been filed or transferred into the newly-formed Dupixent MDL. In a June 11, 2026, order, the Dupixent MDL judge asked the parties to meet and try to reach an agreement on certain case matters before July 24, 2026. The judge also scheduled the initial case management conference (CMC) for October 1, 2026.

June 11, 2026: Tennessee Dupixent Patient Sues Sanofi and Regeneron After Lymphoma Diagnosis

A man from Tennessee has filed a lawsuit against Dupixent’s manufacturers, Sanofi and Regeneron. According to his legal complaint, he was prescribed Dupixent to treat his atopic dermatitis (eczema) from January 2025 to September 2025. His lawsuit claims that he was diagnosed with a type of cutaneous T-cell lymphoma around September 2025. He alleges that his Dupixent use may have caused or contributed to his development of lymphoma and that he should have been warned about this risk.

June 5, 2026: Judicial Panel Approves Request to Create Dupixent MDL

The Judicial Panel on Multidistrict Litigation (JPML) has approved a request to centralize IN RE: DUPIXENT (DUPILUMAB) PRODUCTS LIABILITY LITIGATION (MDL No. 3180). The multidistrict litigation will be held in the District of New Jersey, and the Honorable Zahid N. Quraishi will oversee the MDL. At this time, patients who took Dupixent (dupilumab) and were diagnosed with Cutaneous T-cell Lymphoma (CTCL) may qualify to join the MDL. People may also be eligible to join the MDL if their loved one passed away after taking Dupixent and developing CTCL. However, the JPML said the future MDL criteria could include other types of T-cell lymphomas.

April 16, 2026: Panel Will Hear Request for Creating a Centralized Lawsuit for Those Alleging CTCL From Dupixent

A motion has been submitted to the Judicial Panel on Multidistrict Litigation (JPML) to create a Dupixent multidistrict litigation (MDL) for patients alleging their CTCL was unmasked or induced by the drug. If the JPML approves this request, a federal centralization litigation would be created for Dupixent patients alleging that Dupixent contributed to their blood cancer diagnosis. A previous motion was heard in February 2026, but no action was taken at that time. The JPML will hold a hearing on May 28, 2026. If they create an MDL for Dupixent, plaintiffs will have new legal options for filing their civil lawsuit. There are 15 Dupixent lawsuits in the original centralization motion.

February 13, 2026: Attorneys File Motion to Consolidate Dupixent Lawsuits into a Single Federal MDL

Attorneys representing 15 plaintiffs have filed a motion requesting the Judicial Panel on Multidistrict Litigation (JPML) to create a multidistrict litigation (MDL) for people claiming injuries from Dupixent. In their lawsuits, the plaintiffs allege that taking Dupixent (dupilumab) may be associated with either developing or masking their cutaneous T-cell lymphoma (CTCL). If the JPML approves this request, an MDL would be created. Regeneron is named as the defendant. An MDL is a type of federal, centralized litigation that allows some pre-court proceedings to be combined for all plaintiffs and defendants. Attorneys have requested that the potential Dupixent MDL (i.e., In re Dupixent Products Liability Litigation) be consolidated in U.S. federal courts in the Northern District of Georgia. This MDL would give people filing Dupixent lawsuits an additional venue to seek legal recourse.

Why Are People Filing Dupixent Lawsuits?

Patients are filing lawsuits alleging that using Dupixent contributed to them developing cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin lymphoma. In their lawsuits, patients allege that Dupixent either contributed to or masked their CTCL. Plaintiffs in these lawsuits say that Dupixent’s manufacturers should know about this possible association, yet they do not warn patients.

Is the Dupixent Lawsuit a Class Action Lawsuit or an MDL?

On June 5, 2026, the Judicial Panel on Multidistrict Litigation (JPML) centralized lawsuits involving Dupixent CTCL claims into a multidistrict litigation (MDL). The name of the MDL No. 3180 is In re: Dupixent (Dupilumab) Products Liability Litigation. This motion moves Dupixent lawsuits to a federal court in the District of New Jersey under the Honorable Judge Zahid N. Quraishi. The MDL structure allows each patient to have their case heard individually, and multiple patients can pool resources during the early stages of the legal process.

Who is Eligible to File a Dupixent Lawsuit?

People who want to file a lawsuit against one of Dupixent’s manufacturers will need to meet certain eligibility criteria to file a case. Here are some of the people who may be eligible to file a Dupixent Lawsuit:

• A person who used Dupixent and who was later diagnosed with cutaneous
  T-cell lymphoma (CTCL)
• Spouses of people who developed CTCL after Dupixent use (alleging loss of consortium/companionship)
• Spouses or other survivors of patients who used Dupixent, developed CTCL, and later passed away (alleging wrongful death)

Additionally, when the JPML created the Dupixent MDL, the transfer order stated, “At this stage, we need not rule on whether cases involving T-cell lymphomas other than CTCL belong in this MDL.” This means that if the judge sees enough evidence that Dupixent could be related to developing other types of lymphoma, people with other types of lymphoma may be able to join the MDL.

What Other Conditions May Qualify Someone to File a Dupixent Lawsuit with King Law?

People who want to file a lawsuit against the manufacturers of Dupixent need to meet certain eligibility criteria to file a lawsuit within the MDL. Currently, the Dupixent MDL is accepting CTCL cases, but the JPML judge left room for other qualifying conditions to be accepted in the future. So, in addition to CTCL, our attorneys are reviewing cases from people who were prescribed Dupixent and then developed one of the following conditions:

• Adult T-cell leukemia/lymphoma
• Anaplastic large cell lymphoma
• Extranodal NK-cell/T-cell lymphoma
• Follicular helper T-cell lymphoma
• Lymphomatoid papulosis
• Mycosis fungoides
• Peripheral T-cell lymphoma
• Sézary Syndrome
• Subcutaneous panniculitis-like T-cell lymphoma

If you are unsure if you or a family member qualifies for a lawsuit, please reach out to our firm for a free case evaluation. The types of lymphoma that will qualify for a Dupixent lawsuit will change as the litigation progresses, and King Law will stay current on eligibility requirements.

What Evidence is Needed to File a Dupixent Lawsuit?

To file a Dupixent lawsuit, plaintiffs will need to support their legal complaints with evidence. Their attorney will use this evidence and a wealth of other information to build a strong case. Possible evidence that a plaintiff will have to supply to support a Dupixent law claim includes:

• Prescriptions and records showing when Dupixent was administered and for how long
• Medical records showing a CTCL diagnosis
• Records of treatments for CTCL
• Employment and financial records to document losses
• Personal and witness statements documenting the impacts of the disease

An attorney can advise what records are needed to support a Dupixent claim. They will also ensure that all necessary information is submitted to the courts complete and on time, in order to maintain a viable claim against Dupixent’s manufacturers.

What Are the Allegations in Dupixent Lawsuits?

Allegations against Dupixent’s manufacturers include:

• Failing to warn of possible serious injuries associated with using Dupixent, including the development or exacerbation of CTCL
• Failing to understand, test, and monitor health outcomes in people who took Dupixent
• Knowing about the possible relationship between Dupixent and CTCL and not taking the proper actions
• Improperly marketing Dupixent
• Engaging in negligent marketing practices

Lawsuits also accuse Sanofi, Regeneron, and Genzyme of downplaying the potential risks of the drug. For example, CTCL can look like atopic dermatitis (eczema) in its early stages, so some patients experienced a delay in their cancer diagnoses. Plaintiffs in lawsuits say they should have been told about possible delays in diagnosing CTCL.

Lawsuits say that if the companies had properly monitored Dupixent, stayed current with scientific literature, and properly followed FDA post-market responsibilities, the manufacturers would have been aware of a possible connection between Dupixent and developing CTCL.

Is There a Connection Between Dupixent and T-Cell Lymphoma (CTCL)?

Dupixent suppresses certain inflammatory pathways, which is why it can be a useful treatment for some inflammatory skin and lung conditions. However, this suppression may make it more difficult for the body to detect abnormal T-cell growth and T-cell lymphoma.

In its early stages, CTCL can resemble eczema or another atopic dermatitis. So, some researchers have explored whether Dupixent (dupilumab) may accelerate an undiagnosed lymphoma in some patients or delay its diagnosis. For example, in a paper published in the Journal of the American Academy of Dermatology , researchers said, “We believe that the association between dupilumab and CTCL is explained by dupilumab treatment unmasking preexisting CTCL.”

Scientists are still trying to determine if Dupixent increases the risk of or masks CTCL. Some researchers suspect that Dupixent may reveal or trigger pre-existing CTCL rather than causing it directly.

About Dupixent and Possible Lymphoma Risk

Medical research and safety data show a possible association between Dupixent (dupilumab) use and CTCL and other types of lymphomas, though more research is needed to understand if there is an association. For example, one scientific study found that patients using Dupixent are 4 times more likely to develop CTCL. However, researchers did not determine causality.

CTCL is a rare type of cancer, affecting 8.55 per 1 million people between 2000 and 2018. However, another study has found that Dupixent patients who are taking the medication for atopic dermatitis are 4.59 times more likely to be diagnosed with CTCL than those who have atopic dermatitis and are not on Dupixent.

The data suggest that adult patients are more likely to be diagnosed with CTCL within their first year after starting Dupixent. All of the eczema patients in the control group were over 60 when diagnosed with CTCL. But, only half of the Dupixent eczema patients were 60 or older when diagnosed with CTCL. These data support that taking Dupixent may lead to CTCL at a younger age. However, more research is needed to understand differences among people of different ages.

FDA Alert for Patients Taking Dupixent (Dupilumab)

As of 2026, Dupixent (dupilumab) is listed on the FDA’s list of Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS). According to reports, the agency is investigating the risk level of developing CTCL after receiving Dupixent injections. The FDA is evaluating the need for regulatory action.

Studies About Dupixent and T-Cell Lymphoma

Some research has found a possible association between Dupixent use and CTCL in patients with atopic dermatitis (eczema), COPD, and asthma. Some of these studies have explored increased CTCL rates among Dupixent users compared to the general population and those with eczema who have not taken Dupixent. Scientists are still working to understand if there is a possible association between Dupixent and CTL.

Study Highlight: Dupixent and the Risk of Cutaneous T-Cell Lymphoma

Study name: Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study

Study authors and publish year: Hasan et al., 2024

Study summary: Researchers studied a group of people who were diagnosed with atopic dermatitis (eczema) and prescribed Dupixent. The researchers discovered that those who took Dupixent for their eczema were four times more likely to develop CTCL than those who had eczema and were not given Dupixent. In this study, most of the CTCL diagnoses occurred after the patients had been taking Dupixent for at least a year.

The researchers noted that the study tracked an increased risk of Dupixent patients being diagnosed with CTCL, but they did not look into whether Dupixent causes this type of cancer. Additionally, since they used data from a database, the researchers said misclassifications might be included in their sample. However, the findings add to a body of research showing similar associations between Dupixent and CTCL, and additional investigation is warranted.

Study Highlight: Adverse Events and Severe Side Effects Reported to FDA

Study name: Analysis and mining of Dupilumab adverse events based on FAERS database (FAERS Disproportionality Analysis)

Study authors and publish year: Gao et al., 2025

Study summary: A study of FDA adverse event data showed a possible connection between Dupixent and CTCL. Although the rates of CTCL were low, the researchers noted that it could be a new type of adverse event being reported. The authors encouraged future research into how Dupixent interacts with the immune system and may increase the risk of CTCL.

Study Highlight: The Relationship Between Dupilumab and CTCL

Study name: Case Report: Cutaneous T-cell lymphoma associated with biologic therapy: three cases and a literature review (Case Series & Literature Review)

Study authors and publish year: Li et al., 2025

Study summary: Researchers examined the relationship between Dupixent use and CTCL. The researchers discovered that 27 out of 31 patients with atopic dermatitis who were given Dupixent (dupilumab) developed a form of CTCL thereafter.

The authors noted that atopic dermatitis and early forms of CTCL look very similar in their early stages, so more research is needed to determine the relationship between Dupixent and this type of cancer. Dupixent may alter the immune system in a way that opens the door for CTCL to develop. Similarly, it may unmask the condition in someone who has or is predisposed to have it. Nonetheless, given the strong association between Dupixent and CTCL, the study concludes that caution is warranted in diagnosing and treating eczema patients with Dupixent.

What Is Dupixent (Dupilumab) and How Does It Work?

Dupixent (dupilumab) is a prescription drug called a biologic medication. It is given as an injection to treat various skin and respiratory conditions. It acts as an interleukin inhibitor, which means it blocks certain proteins that promote inflammation. It belongs to a class of drugs called monoclonal antibodies. It was originally approved by the FDA in 2017 to treat eczema, but it has been approved for other conditions, including asthma, in 2018.

The FDA has approved Dupixent to treat the following nine conditions:

• Moderate to severe eczema: Approved for moderate to severe chronic atopic dermatitis
• Asthma: Approved as an add-on maintenance treatment for uncontrolled moderate-to-severe eosinophilic or oral steroid-dependent asthma
• Chronic obstructive pulmonary disease (COPD): Approved as an additional treatment for inadequately controlled COPD with high blood eosinophils
• Chronic rhinosinusitis with nasal polyps (CRSwNP): Approved as an add-on maintenance treatment for uncontrolled nasal polyps
• Eosinophilic esophagitis (EOE): Approved to treat an inflamed esophagus caused by too many white blood cells
• Chronic spontaneous urticaria (CSU): Approved for treatment of hives not controlled by H1 antihistamines
• Bullous pemphigoid (BP): Approved to treat a skin condition that causes itchy, fluid-filled blisters
• Prurigo nodularis (PN): Approved to treat a skin condition that causes severe itching
• Allergic fungal rhinosinusitis (AFRS): Approved to treat some nasal symptoms and inflammation

Dupixent changes how your immune system works, with the goal of preventing your body from reacting to substances that are not an actual threat. Specifically, Dupixent turns off the IL-4 and IL-13 protein immune pathways. These proteins tell your body to become inflamed in response to attacks on your immune system. However, in people with conditions like eczema or asthma, the body has an inflammatory response to triggers that are not threats.

Dupixent helps calm down the skin irritation, redness, lesions, and inflammation that people experience when they have eczema that other medications have not helped. Dupixent is also offered to patients with treatment-resistant chronic obstructive pulmonary disease (COPD) or asthma.

While many people have experienced relief when taking Dupixent, some people have developed CTCL after taking the drug. Because of this, patients are filing lawsuits alleging that Dupixent’s manufacturer did not properly warn them of the possible risks associated with the drug.

Overview of Dupixent.

Timeline of FDA Approvals for Dupixent

June 2025: FDA Approves Dupixent to Treat Painful Skin Condition Called BP

Despite some safety concerns, the FDA approved Dupixent for the treatment of bullous pemphigoid (BP) on June 20, 2025. At the time, it was the only targeted treatment available to BP patients in the U.S. The disease causes large fluid-filled blisters to appear on the skin, often near creases in the skin.

April 2025: FDA Approves Dupixent to Treat Skin Condition Called CSU

On April 18, 2025, the FDA approved Dupixent to treat chronic spontaneous urticaria (CSU), the first new treatment for the disease in more than 10 years. CSU is a condition where a person develops chronic hives, with episodes often lasting for 6 weeks or more.

September 2024: FDA Approves Dupixent to Treat COPD

On September 27, 2024, the FDA approved Dupixent to treat certain cases of chronic obstructive pulmonary disease (COPD). The drug is approved as an add-on treatment for adults whose COPD is not adequately controlled and of the eosinophilic phenotype (a subtype of COPD). Dupixent is the first biologic medicine receiving FDA approval for people with COPD.

May 2022: FDA Approves Dupixent as A Treatment for EOE

Another approval is granted to Sanofi and Regeneron for their biologic drug Dupixent. Dupilumab is granted approval to treat eosinophilic esophagitis (EOE) as a first-line treatment for people ages 12 and older. The FDA would grant approval for the drug to be used in children ages 1 and older, as the first and only treatment for children with EOE.

June 2019: FDA Approves Dupixent for Treatment of Chronic Nasal Polyps

On June 26, 2019, the FDA gives their approval for Dupixent to be used as a treatment for chronic rhinosinusitis with nasal polyposis (CRSwNP). This approval is given for adults whose disease is not controlled through other treatments or medications. On September 13, 2024, the FDA would approve Dupixent as the first and only treatment for adolescents with CRSwNP.

March 2019: FDA Approves Dupixent As Treatment for Atopic Dermatitis in Adolescents

The FDA gives approval for adolescents to receive Dupixent injections to treat their moderate-to-severe atopic dermatitis and eczema. This means the drug is approved for administration in patients 12 to 17 years old. The FDA would later grant approval for use in patients 6 to 11 years old. This second approval came in May of 2020.

October 2018: FDA Gives Second Approval to Dupixent for Treating Asthma

On October 19, 2018, Sanofi announced that the FDA approved Dupixent to treat certain types of asthma. The approval is given to Dupixent as an add-on maintenance therapy in patients with moderate-to-severe asthma. It is approved for ages 12 and up and for people with eosinophilic phenotype or oral corticosteroid-dependent asthma. The FDA would later approve the drug for children ages 6 to 11 who have moderate-to-severe asthma.

March 2017: FDA Approves Biologic Drug Called Dupixent (Dupilumab) to Treat Eczema and Atopic Dermatitis (AD)

On March 28, 2017, Regeneron and Sanofi announced the FDA’s approval of their new drug, Dupixent. The initial approval is given for treating moderate-to-severe atopic dermatitis (the most common form of eczema) in adults. It is the targeted biologic therapy for adults with the condition, which is a chronic inflammatory disease of the skin. It can cause debilitating pain and itching. At the time of Dupixent’s approval, Regeneron says it is estimated that 300,000 people are in need of new treatment options for their atopic dermatitis (eczema).

What Damages Could Be Recovered in a Dupixent Lawsuit?

Patients who take Dupixent and develop CTCL may be able to recover compensation for their associated losses. Damages they may be eligible for include:

• Medical costs
• Lost income and earning potential
• Pain and suffering
• Loss of quality of and enjoyment in life
• Wrongful death damages (recoverable by eligible family members if the patient dies because of cutaneous T-cell lymphoma)

Patients can support their claim for damages by presenting medical testing results (like biopsies), treatment records, prescription costs, and work history (including requests for time off for cancer treatments). Surviving family members may also be able to recover funeral and burial expenses, loss of financial and emotional support, mental anguish, and other forms of compensation.

Is There a Deadline to File a Dupixent Lawsuit?

Yes, there is a deadline to file a Dupixent lawsuit. The deadline depends on a variety of criteria, including which state you file your lawsuit in, what state you live in, and other factors. This deadline is called the statute of limitations, and it varies by state and claim type. Typically, the deadline depends on when a person is diagnosed or when they discover the possible association between Dupixent and their CTCL diagnosis.

However, some exceptions can push this deadline forward or backward, and different deadlines apply to wrongful death claims. Swift action is recommended to minimize the risk of missing out on compensation due to missed due dates. Personal injury attorneys can help you determine what your deadline is and help you meet it.

What Are the Estimated Settlement Amounts in a Dupixent Lawsuit?

Dupixent settlement amounts will vary based on the person’s individual circumstances, the applicable state law, and other factors. Speculative Dupixent settlements could range from $50,000 to $500,000, based on similar drug liability lawsuits. However, this is only an estimate based on similar cases filed for other drugs. There is no guaranteed payout amount, and not all people who file lawsuits will qualify for compensation.

King Law Is Investigating Dupixent and T-Cell Lymphoma Claims

King Law and our legal partners are actively accepting and reviewing claims by patients who took Dupixent and developed CTCL. We have extensive experience fighting for consumers who were harmed by dangerous pharmaceutical products they were told would help them. Some of the benefits of working with us include:

• We do not charge upfront legal fees to hire us or book an appointment with us (we take all cases on contingency, meaning you only pay us if and when you win).
• We provide free case evaluations.
• We have a proven track record of helping patients who were hurt by dangerous drugs and medical devices.
• We have a robust network of resources to help us build strong cases.
• We have a dedicated, in-house intake team. You will not be sent to a generic call center.
• We are dedicated to helping people harmed by corporate negligence.

We treat our clients like people, not dollar figures. We take the time to get to know you, your concerns, and what a successful outcome means to you. Our full-service law firm is here to help you pursue justice because of how Dupixent has harmed you.

Contact a Dupixent Lawyer Today

If you took Dupixent and were diagnosed with cutaneous T-cell lymphoma, you may be eligible for a settlement. Contact us today by calling (585) 496-2648 to schedule a free, no-obligation consultation with an experienced attorney who can help. We can work with you to develop an effective case strategy to maximize your chances of winning a fair payout for your losses.

Frequently Asked Questions (FAQs)

Read Other Updates About Dupixent Lawsuits, Research, and Regulatory Events

List of Sources Used in This Article

Here is a list of sources used to create this article. King Law adheres to rigorous editorial standards when creating pages for our readers.